PSI Recommendation

PSI Mass Spectrometry and Proteomics Informatics Working Groups

Status: DRAFT

Juan Antonio Vizcaíno, EMBL-EBI

Eric W. Deutsch, Institute for Systems Biology

Pierre-Alain Binz, CHUV Lausanne University Hospital

Ryan T. Fellers, Northwestern University

Anthony J. Cesnik, Stanford University

Joshua A. Klein, Boston University

Tim Van Den Bossche, Ghent University

Ralf Gabriels, Ghent University

Yasset Perez-Riverol, EMBL-EBI

Jeremy Carver, University of California San Diego

Shin Kawano, Toyama University of International Studies

Benjamin Pullman, University of California San Diego

Nuno Bandeira, University of California San Diego

Paul M. Thomas, Northwestern University

Richard D. LeDuc, Northwestern University

October 2, 2020

Status of this document

This document provides information to the proteomics community about a proposed standard proteoform and peptidoform notation called ProForma. Distribution is unlimited.

Version Draft 11 - this is a draft of version 2.0

# Abstract

The Human Proteome Organisation (HUPO) Proteomics Standards Initiative (PSI) defines community standards for data representation in proteomics to facilitate data comparison, exchange and verification. This document presents a specification for a proteoform and peptidoform notation, which is based on the ProForma notation.

Further detailed information, including any updates to this document, implementations, and examples is available at <http://psidev.info/proforma>.

Contents

[Abstract 1](#_Toc52531504)

[1. Introduction 4](#_Toc52531505)

[1.1 Description of the need 4](#_Toc52531506)

[1.2 Requirements 4](#_Toc52531507)

[1.3 Issues to be addressed 5](#_Toc52531508)

[2. Notational Conventions 5](#_Toc52531509)

[3. The Peptidoform Notation Definition 5](#_Toc52531510)

[3.1 The documentation 5](#_Toc52531511)

[3.2 Relationship to other specifications 5](#_Toc52531512)

[4. The Basic Form of the Proteoform and Peptidoform Notation 6](#_Toc52531513)

[4.1 The canonical amino acid sequence 6](#_Toc52531514)

[4.2 Generic representation of protein modifications 7](#_Toc52531515)

[4.2.1 Controlled vocabulary or ontology modification names 7](#_Toc52531516)

[4.2.1.1 Definition of the Unimod modification name 8](#_Toc52531517)

[4.2.2 Controlled vocabulary or ontology protein modification accession numbers 8](#_Toc52531518)

[4.2.3 Support for cross-linkers 9](#_Toc52531519)

[4.2.3.1 Crosslink notation (within the same peptide) 9](#_Toc52531520)

[4.2.3.2 Representing inter-chain crosslinks 9](#_Toc52531521)

[4.2.3.3 Representing disulfide linkages 10](#_Toc52531522)

[4.2.4 Representation of glycans using the GNO ontology as CV 10](#_Toc52531523)

[4.2.5 Delta mass notation 11](#_Toc52531524)

[4.2.6 Specifying a gap of known mass 12](#_Toc52531525)

[4.2.7 Support for elemental formulas (e.g. for representing small molecular substructures or functional groups) 12](#_Toc52531526)

[4.2.8 Representation of glycan composition 13](#_Toc52531527)

[4.2.9 Best practises on the use of protein modifications 14](#_Toc52531528)

[4.3 Representation of special cases: N-terminal, C-terminal and labile protein modifications 14](#_Toc52531529)

[4.3.1 N-terminal and C-terminal modifications 14](#_Toc52531530)

[4.3.2 Labile modifications 15](#_Toc52531531)

[4.4 Support for the representation of ambiguity in the modification position 15](#_Toc52531532)

[4.4.1 Unknown modification position 15](#_Toc52531533)

[4.4.2 Indicating a possible set of modification positions 16](#_Toc52531534)

[4.4.3 Representing ranges of positions for the modifications 16](#_Toc52531535)

[4.4.4 Indicating modification position preference and localisation scores 17](#_Toc52531536)

[4.4.5 Representing scoring for ranges of positions for a modification 17](#_Toc52531537)

[4.5 Representation of multiple modifications in the same amino acid residue 17](#_Toc52531538)

[4.6 Representation of global modifications 18](#_Toc52531539)

[4.6.1 Use Case 1: Representation of isotopes 18](#_Toc52531540)

[4.6.2 Use Case 2: Fixed protein modifications 18](#_Toc52531541)

[4.7 The information tag 18](#_Toc52531542)

[4.8 Support for the joint representation of experimental data and its interpretation 19](#_Toc52531543)

[5. Pending Issues - Future developments 20](#_Toc52531544)

[5.1 Representation of cyclic peptides 20](#_Toc52531545)

[5.2 Representation of ambiguity when different glycans are attached to the same amino acid sequence 21](#_Toc52531546)

[5.3 Representation of rare amino acids not supported by the one letter code 22](#_Toc52531547)

[5.4 Representation of average masses 22](#_Toc52531548)

[5.5 Representation of lipids 22](#_Toc52531549)

[5.6 Distribution of isotopes in the sequence 23](#_Toc52531550)

[5.7 Representation of molecular formula 23](#_Toc52531551)

[5.8 Representation of overlapping range of possible modification localizations 23](#_Toc52531552)

[5.9 Representation of ambiguous crosslinker modification positions 23](#_Toc52531553)

[6. Appendix I. Levels of Compliance 24](#_Toc52531554)

[7. Appendix II: Extensions to improve the representation of PSMs in mass spectra 26](#_Toc52531555)

[7.1 Representation of the ion charges 26](#_Toc52531556)

[7.2 Representation of multiple peptidoform assignments in chimeric spectra 26](#_Toc52531557)

[8. Appendix III. Glossary of terms used in the specification 28](#_Toc52531558)

[9. Authors Information 32](#_Toc52531559)

[10. Contributors 33](#_Toc52531560)

[11. Intellectual Property Statement 34](#_Toc52531561)

[12. Copyright Notice 34](#_Toc52531562)

[13. Glossary 35](#_Toc52531563)

[14. References 35](#_Toc52531564)

# Introduction

## **Description of the need**

Protein and peptide sequences are usually represented using a string of amino acids using a well-known one letter code endorsed by the IUPAC (see e.g. <https://wissen.science-and-fun.de/chemistry/biochemistry/iupac-one-letter-codes-for-bioinformatics/>). However, there is still no clear consensus about how to represent ‘proteoforms’ and ‘peptidoforms’. The ‘forms’ suffix means all the possible variations of a protein or peptide sequence, including protein modifications and both artefactual and post-translational modifications (PTMs). There are indeed multiple ways of encoding mass modifications and extended discussion has taken place to achieve a consensus. A standard notation for proteoforms and peptidoforms is then required for the community, so that it can be embedded in many relevant PSI (and potentially other) file formats.

The PSI has developed a format called PEFF (PSI Extended FASTA Format, <http://www.psidev.info/peff>) that can be used to represent proteoforms (1). Additionally, the Consortium for Top Down Proteomics (CTDP) developed a notation format called ProForma (<https://topdownproteomics.github.io/ProteoformNomenclatureStandard/>) (2) that aims to represent proteoforms.

This format specification represents the consensus for the standard representation of proteoforms and peptidoforms. This notation aims to support the main proteomics approaches, including bottom-up (focused on peptides/peptidoforms) and top-down (focused on proteins/proteoforms) approaches.

## **Requirements**

The main requirements to be fulfilled for a proteoform and peptidoform notation are:

* It MUST be a string that is human readable, so it can be generally understood by human individuals.
* It MUST be machine parsable. Other variants of this notation will not be supported computationally, although they could be ‘human readable.’
* It MUST be able to support the encoding of amino acid sequences and protein modifications.
* It MUST be able to support the main use cases needed by the proteomics community as a whole, including both bottom-up (focused on peptides/peptidoforms) and top-down (focused on proteins/proteoforms) approaches.
* It MUST be flexible to accommodate different “flavours” of notations, considering common current use.
* It MUST be compatible with existing PSI file formats, where it could be used.
* It MUST be able to capture ambiguity in the position of the modified sites.
* It MUST be able to evolve, so new use cases can be added iteratively in the future.

## **Issues to be addressed**

The main issues to be addressed by ProForma are:

* It MUST be able to represent peptidoforms and proteoforms in a consistent and reproducible way, considering the different ways of representing protein modifications.
* It MUST be able to be used jointly with the Universal Spectrum Identifier (USI), to represent peptide-spectrum matches (PSMs), and to represent proteoform-spectrum matches (PrSMs).

# Notational Conventions

The key words “MUST”, “MUST NOT”, “REQUIRED”, “SHALL”, “SHALL NOT”, “SHOULD”, “SHOULD NOT”, “RECOMMENDED”, “MAY”, and “OPTIONAL” are to be interpreted as described in RFC 2119 (2).

# The Peptidoform Notation Definition

## **The documentation**

The documentation of the ProForma Notation for proteoform and peptidoforms is divided into several components. All components in their most recent form are available at the HUPO-PSI website (<http://psidev.info/proforma>) and at the ProForma GitHub page (<https://github.com/HUPO-PSI/ProForma/>).

* Main specification document (this document).
* List of current implementations with examples.
  + C# ProForma Parser: <https://github.com/topdownproteomics/sdk>
  + USI implementation (Institute for Systems Biology, URL to be added).

## **Relationship to other specifications**

The format specification described in this document is not being developed in isolation; indeed, it is designed to be complementary to, and thus used in conjunction with, several existing and emerging models. Related specifications include the following:

1. *PSI Universal Spectrum Identifier* (<http://www.psidev.info/USI>). The PSI Universal Spectrum Identifier is designed to provide a universal mechanism for referring to a specific spectrum in public repositories. It can optionally include an interpretation of the spectrum using the notation described in this specification. Displayers of USIs MAY use any of the supported ProForma notations.
2. *mzSpecLib, the PSI spectrum library format* (<http://psidev.info/mzSpecLib>). The PSI spectrum library format is being developed as a standard mechanism for storing spectrum libraries. Identified spectra of modified peptides, will have to include the modification information, potentially in this ProForma notation. Furthermore, many spectrum library entries are derived from multiple spectra, and this provenance will be referenced using USIs.
3. *PROXI* (<http://www.psidev.info/proxi>). The Proteomics Expression Interface being developed by the PSI is a standardized API by which mass spectrometry proteomics information can be exchanged. References to individual spectra will be made via USIs.
4. *PEFF* (<http://www.psidev.info/peff>).The PSI Extended Fasta Format enables the representation of proteoforms (1).
5. *ProForma* (<http://psidev.info/proforma>)*.* ProForma Proteoform Notation version 1, which enables the representation of proteoforms (<https://topdownproteomics.github.io/ProteoformNomenclatureStandard/>), developed by the CTDP (2). This specification is subsumed by this new version 2 ProForma specification.

# The Basic Form of the Proteoform and Peptidoform Notation

The ProForma notation is a string of characters that represent linearly one or more peptidoform/proteoform primary structures with possibilities to link peptidic chains together. It is not meant to represent higher order structures.

ProForma is case insensitive. However, within the data that follows the different keys, capitalisation may be important. In that case, capitalisation sensitivity is the decision of the supported CVs/ontologies.

Since ProForma MAY be used to represent both peptidoforms and proteoforms, there is currently no limit in its maximum length. Line breaks MUST NOT be used. However, non-ASCII characters are also allowed since non-ASCII characters can be included in the supported ontologies and controlled vocabularies (CVs).

Due to the multiple use cases supported in this specification, it is not expected that all implementers can provide support to all the supported features from ProForma. To facilitate adoption and separate some of the use cases, there are multiple “levels of compliance” and extensions for ProForma, which are summarised in Appendix I.

## **The canonical amino acid sequence**

Amino acid sequences are represented by strings of amino acids represented as characters using the one letter code endorsed by the IUPAC (<http://publications.iupac.org/pac/1984/pdf/5605x0595.pdf>

and <https://wissen.science-and-fun.de/chemistry/biochemistry/iupac-one-letter-codes-for-bioinformatics/>). There are also letters for representing ambiguous and/or unusual amino acids (see <http://www.insdc.org/documents/feature_table.html#7.5.3>), which are used in some UniProt entries. Some examples are:

- B: Aspartic Acid or Asparagine

- Z: Glutamic Acid or Glutamine

- J: Leucine or Isoleucine

- U: Selenocysteine

- O: Pyrrolysine

- X: Any amino acid (see also Section 4.2.6 Specifying a gap of known mass, for the use of X). We note that the character X itself is assigned zero mass in this notation.

The representation of non-linear peptides is NOT formalised in this version of ProForma. See the section 5.3 (“Representation of cyclic peptides”) in *Section 5: Pending Issues*, for possible ways to represent them.

## **Generic representation of protein modifications**

It has been decided that multiple formats and reference systems must be supported, because some flexibility is required. The same approach is followed for both artefactual protein modifications and natural PTMs. Square brackets MUST be used to represent them when the position is unambiguous. They are located after the character representing the modified amino acid. If there is ambiguity in the position of the protein modification, different rules apply (see section 3.3.4).

Five different reference systems for protein modifications are supported including the following CVs and/or ontologies:

- Unimod (<http://www.unimod.org/>).

- PSI-MOD (<https://www.ebi.ac.uk/ols/ontologies/mod>).

- RESID (<https://proteininformationresource.org/resid/>). Although RESID is included in PSI- MOD, this reference system is still used in the top-down community.

- XL-MOD (<https://raw.githubusercontent.com/HUPO-PSI/mzIdentML/master/cv/XLMOD.obo>) MUST be used for the representation of cross-linkers.

- GNO (Glycan Naming Ontology, <https://www.ebi.ac.uk/ols/ontologies/gno>).

### **Controlled vocabulary or ontology modification names**

The names from different CV or ontology terms MAY be used to represent protein modifications. The two main reference systems used are Unimod and PSI-MOD. However, to facilitate differentiation between reference systems for readers, the names coming from other three supported CV/ontology MUST be preceded by a letter and colon, indicating the originating CV/ontology. In the case of Unimod and PSI-MOD, the use of prefixes is optional.

Examples of proper modification name usage:

- Unimod: U (optional)

- PSI-MOD: M (optional)

- RESID: R (mandatory)

- XL-MOD: X (mandatory)

- GNO: G (mandatory)

EM[Oxidation]EVEES[Phospho]PEK

EM[L-methionine sulfoxide]EVEES[O-phospho-L-serine]PEK

EM[R: Methionine sulfone]EVEES[O-phospho-L-serine]PEK

EMEVTK[X:DSS#XL1]SESPEK (see Section 4.2.3)

In the case of GNO, the use of accession numbers is preferred since accession numbers and names are often the same. Example:

NEEYN[GNO:G59626AS]K is preferred over NEEYN[G:G59626AS]K

Prefixes can still be used for Unimod and PSI-MOD names (but it is not included in basic support, see Appendix I):

EM[U:Oxidation]EVEES[U:Phospho]PEK

EM[M:L-methionine sulfoxide]EVEES[M:O-phospho-L-serine]PEK

Special characters do not need to be escaped. The only restriction is that unpaired bracket characters MUST NOT be used. Example of properly paired internal brackets:

EM[Oxidation]EVE[Cation:Mg[II]]ES[Phospho]PEK

For different reference systems not supported explicitly, the tag ‘INFO’ MUST be used (see Section 4.7).

#### Definition of the Unimod modification name

The Unimod OBO file SHOULD be used: <http://www.unimod.org/obo/unimod.obo>. Within this file, term names are found in the “name” tag. These terms differ in the Unimod web interface (<http://www.unimod.org/>). There, the equivalent to the “name” field in the OBO file is the “PSI-MS Name” column, if not empty (if there is a value). If the “PSI-MS Name” field is empty, the “interim name” is used. Unimod synonyms are currently NOT supported, as they are provided inconsistently.

### **Controlled vocabulary or ontology protein modification accession numbers**

The accession numbers of the various terms from supported CVs and ontologies MUST be used (no abbreviations are allowed). The supported names are:

- Unimod: UNIMOD

- PSI-MOD: MOD

- RESID: RESID

- XL-MOD: XLMOD

- GNO: GNO

Examples of proper accession number usage:

EM[MOD:00719]EVEES[MOD:00046]PEK

EM[UNIMOD:15]EVEES[UNIMOD:56]PEK

EM[RESID:AA0581]EVEES[RESID:AA0037]PEK

### **Support for cross-linkers**

Support for cross-linkers is possible by using the XL-MOD CV. It is acknowledged that the current version of ProForma does not provide support for all possible use cases involving cross-linked peptides. In the future, it is expected that a specific extension for this type of information can be developed.

Using the XL-MOD CV, crosslinked sites MUST represented immediately following the modification notation using the prefix #XL, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Cross-linker modification notations MUST be mentioned once only.

#### Crosslink notation (within the same peptide)

Cross-linker modification notations MUST be mentioned once only. This example shows a DSS crosslink between two lysines:

EMEVTK[XLMOD:02001#XL1]SESPEK[#XL1]

This second example shows a DSS crosslink between two lysines and a BS3 cross-link between two other lysines:

EMK[XLMOD:02000#XL1]EVTK[XLMOD:02001#XL2]SESK[#XL1]PEK[#XL2]

A “dead end” crosslink happens regularly with bifunctional crosslinkers when one side attaches and the other hydrolyses before attaching. These modifications are annotated at only one site.

EMEVTK[XLMOD:02001#XL1]SESPEK

EMEVTK[XLMOD:02001]SESPEK

#### Representing inter-chain crosslinks

Inter-protein or inter-chain connections are supported using \\ to separate the crosslinked peptides. This notation is similar to IUPAC condensed notation for inter-protein connections.

SEK[XLMOD:02001#XL1]UENCE\\EMEVTK[XLMOD:02001#XL1]SESPEK

SEK[XLMOD:02001#XL1]UENCE\\EMEVTK[#XL1]SESPEK

It is acknowledged by the authors that more complex scenarios are possible when representing inter-chain crosslinks, including a higher number of linked peptides, directionality, etc. It is envisioned that when these use cases become a clear requirement in the future, a dedicated working group can extend these guidelines.

#### Representing disulfide linkages

Disulfide bonds may be represented using three possible notations:

(i) Using the PSI-MOD term for “L-cystine (cross link)” (MOD:00034) to explicitly describe the cross-link using the cross-linking notation:

EVTSEKC[MOD:00034#XL1]LEMSC[#XL1]EFD

EVTSEKC[L-cystine (cross-link)#XL1]LEMSC[#XL1]EFD

There are more complex examples that are possible. For instance, another example with inter-chain disulfide bonds is insulin:

FVNQHLC[MOD:00034#XL1]GSHLVEALYLVC[MOD:00034#XL2]GERGFFYTPKA\\GIVEQC[MOD:00034#XL3]C[#XL1]TSIC[#XL3]SLYQLENYC[#XL2]N

As mentioned above, more complex scenarios are possible which will need to be resolved in future versions.

(ii) Using the XLMOD term XLMOD:02009 similarly to case (i) above:

EVTSEKC[XLMOD:02009#XL1]LEMSC[#XL1]EFD

EVTSEKC[X:Disulfide#XL1]LEMSC[#XL1]EFD

(iii) Using the PSI-MOD term for “half-cystine” (MOD:00798) if the pairing is not known. Since the term is only for half the link, it must be specified on all involved sites with no group tag:

EVTSEKC[half-cystine]LEMSC[half-cystine]EFD

EVTSEKC[MOD:00798]LEMSC[MOD:00798]EFDEVTSEKC[MOD:00798]LEMSC[MOD:00798]EFD

### **Representation of glycans using the GNO ontology as CV**

Glycans that are currently included in Unimod or PSI-MOD (individual or very short chains) MAY be represented that way. If the glycans are not included in either PSI-MOD or Unimod, the GNO ontology SHOULD be used. As mentioned above, the use of accession numbers is preferred since accession numbers and names are often the same.

Examples of proper glycan notation:

Encoding Hex 5 HexNAc 4 NeuAc 1:

NEEYN[GNO:G59626AS]K

Encoding Hex 8 HexNAc 2 and Hex 5 HexNAc 2:

YPVLN[GNO:G62765YT]VTMPN[GNO:G02815KT]NSNGKFDK

The same mechanisms for expressing labile modifications and ambiguity in the modification position applicable to other types of modifications SHOULD be used for glycans as well (see following sections, e.g. Sections 4.3.2 and 4.4).

There are more complex cases, where ambiguity can be caused by multiple combinations between labile and non-labile glycans attached to the same amino acid sequence. A possible mechanism to represent these more complex cases is available in Section 5 (*Pending issues*). A further limitation comes from the restricted set of glycans in GNO. We expect that these issues will be solved as the glyco(proteomics) community develops in the near future.

### **Delta mass notation**

In addition to using CV/ontologies names and/or accession numbers, mass differences (delta masses) MAY be used to represent protein modifications.

Delta masses SHOULD only be used when the protein modification cannot be represented using a CV/ontology, when it is ambiguous (e.g., coming from open modification searches), or when it is unknown. Otherwise, protein modifications SHOULD be represented using Unimod, PSI-MOD, RESID, XL-MOD, or GNO CV parameters.

Mass differences MUST be expressed in Daltons between the coded amino acid and the observed mass. Positive mass shifts MUST be specified with a plus sign. Negative shifts must be specified with a negative sign. Monoisotopic masses MUST be used. There are two ways of representing delta masses:

A) Without using prefixes.

EM[+15.9949]EVEES[+79.9663]PEK

EM[+15.995]EVEES[-18.01]PEK

Interpretation of the actual delta masses is then left to the reader software.

B) Using prefixes for CVs/ontologies to provide more information.

If “canonical” delta masses are directly taken from a CV/ontology, the corresponding abbreviation to that CV/ontology MAY be used.

- Unimod: U

- PSI-MOD: M

- RESID: R

- XL-MOD: X

- GNO: G

Examples of delta masses corresponding to CV/ontology entries:

EM[U:+15.9949]EVEES[U:+79.9663]PEK

EM[U:+15.995]EVEES[U:+79.966]PEK

The notation also supports the encoding of experimentally observed delta masses. In those cases, the prefix “Obs” MUST be used. The number of significant figures included in the delta mass depends on the accuracy of the available data and SHOULD be used as is by interpreters. Example:

EM[U:+15.995]EVEES[Obs:+79.978]PEK

### **Specifying a gap of known mass**

This mechanism can be used to express a gap in the sequence of an unknown number of amino acids, but the corresponding mass difference is known. This is supported by the use of the character X followed by brackets indicating the total mass of the gap, meaning that the mass of X is actually zero.

Example of proper gap notation:

RTAAX[+367.0537]WT

### **Support for elemental formulas (e.g. for representing small molecular substructures or functional groups)**

A modification representing a small molecular substructure or a functional group can be described by a chemical formula. The descriptor “Formula” MUST be used. Only elemental formulas are supported. Chemical formulas

Example of proper chemical formula usage:

SEQUEN[Formula:C12H20O2]CE

SEQUEN[Formula:[13C2]CH6N]CE

As no widely accepted specification exists for expressing elemental formulas, we have adapted a standard with the following rules (taken from <https://github.com/rfellers/chemForma>):

Formula Rule 1

A formula will be composed of pairs of atoms and their corresponding cardinality (two Carbon atoms: C2). Pairs SHOULD be separated by spaces but are not required to be. Atoms and cardinality SHOULD NOT be. Also, the Hill system for ordering (<https://en.wikipedia.org/wiki/Chemical_formula#Hill_system>) is preferred, but not required.

Example: C12H20O2 or C12 H20 O2

Formula Rule 2

Cardinalities must be positive or negative integer values. Zero is not supported. If a cardinality is not included with an atom, it is assumed to be +1.

Example: HN-1O2

Formula Rule 3

Isotopes will be handled by prefixing the atom with its isotopic number in square brackets. If no isotopes are specified, previous rules apply. If no isotope is specified, then it is assumed the natural isotopic distribution for a given element applies.

Example: [13C2][12C-2]H2N

Example: [13C2]C-2H2N

SEQUEN[Formula:[13C2][12C-2]H2N]CE

(here 2 12C atoms are replaced by 2 13C atoms)

See in Section 5 (*Pending issues*) how this mechanism could be extended in the future to support more complex molecular formulas.

### **Representation of glycan composition**

Glycan residues (generic monosaccharides) can be represented using the descriptor “Glycan”. If glycan symbols conflict with themselves or element symbols in such a way that ambiguities occur, we will consider requiring spaces between 'atoms' (see Formula Rule #1).

Example: Hex2HexNAc

SEQUEN[Glycan:HexNAc1Hex2]CE

The supported list of monosaccharides in ProForma is included below. It is worth noting that the masses and elemental compositions included below for each monosaccharide are those resulting after each of them are condensed with the amino acid chain.

Hex: Hexose, 162.0528 Da, C6H10O5

HexNAc: N-Acetyl Hexose, 203.0793 Da, C8H13N1O5

HexS: Hexose Sulfate, 242.009 Da, C6H10O8S1

HexP: Hexose Phosphate, 242.0191 Da, C6H11O8P1

HexNAcS: N-Acetyl Hexose Sulfate, 283.0361 Da, C8H13N1O8S1

dHex: Deoxy-Hexose, 146.0579 Da, C6H10O4

NeuAc: N-acetyl Neuraminic Acid / Sialic Acid, 291.0954 Da, C11H17N1O8

NeuGc: N-glycolyl Neuraminic Acid, 307.0903 Da, C11H17N1O9

Pen: Pentose, 132.0422 Da, C5H8O4

Fuc: Fucose, 146.0579 Da, C6H10O4 (a particular stereochemical assignment of dHex abundant in mammals)

However, we envision that more monosaccharides could be added once this specification document is formalised. An updated list of supported monosaccharides (in two different formats, obo and json) can be found at:

<https://github.com/HUPO-PSI/ProForma/tree/master/monosaccharides>

For other glycans not included there, a new CV term will need to be created, e.g. in PSI-MOD.

It is recognised that this mechanism is limited and can only support the most common glycans. It is envisioned that in the future, when this use case becomes a requirement, a dedicated working group can work in extending these specific guidelines. See Section 5 (*Pending issues*) for guidance on future extensions of this mechanism to support other macromolecules, e.g. lipids.

### **Best practises on the use of protein modifications**

In the same sequence, the same reference system SHOULD be used to represent the protein modifications. However, the delta mass notation (Section 4.2.5) MAY be combined with the other cases.

## **Representation of special cases: N-terminal, C-terminal and labile protein modifications**

### **N-terminal and C-terminal modifications**

The square brackets containing the modification MUST be located before the first amino acid in the sequence or after the last amino acid in the peptide sequence. In both cases, they are separated by a dash (-). Examples:

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK

[iTRAQ4plex]-EM[U:Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

### **Labile modifications**

Labile modifications are those which are known to separate under certain experimental conditions during fragmentation and therefore are not visible in the fragmentation MS2 spectrum (i.e. the MS2 spectra are indistinguishable from spectrum not containing the modification). They are represented by curly brackets {}, not by square ones. As explained in Section 4.2.8, the prefix “Glycan:” needs to be added for each labile monosaccharide. Examples:

{Glycan:Hex}EM[U:Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

{Glycan:Hex}[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

{Glycan:Hex}[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

One can also express multiple labile modifications using the following notation:

{Glycan:Hex}{Glycan:NeuAc}EMEVNESPEK

## **Support for the representation of ambiguity in the modification position**

This notation is used to represent ambiguous modified sites, associated positions and associated probabilities or scores.

This notation is not yet supported for crosslinker modifications (see Section 5.9), except for the case of disulfide cross-linkers which may be represented with ambiguous position using the PSI-MOD term for “half-cystine” (MOD:00798), as noted in Section 4.2.3.3.iii.

### **Unknown modification position**

The positions of some modifications may be unknown. In this case, protein modifications are represented using square brackets located on the left side of the amino acid sequence. The symbol ‘?’ is used to indicate that the actual position of the modification is unknown.

[Phospho]?EM[Oxidation]EVTSESPEK

In case of multiple modifications with an unknown location, two options are possible to represent them:

(i) Listing them separately as in this example of two phosphorylations:

[Phospho][Phospho]?[Acetyl]-EM[Oxidation]EVTSESPEK

(ii) Indicating the concrete modification only once but using the caret (^) symbol to represent the number of occurrences of the modification.

[Phospho]^2[Methyl]?[Acetyl]-EM[Oxidation]EVTSESPEK

N-terminal modifications MUST be the last ones written, just next to the sequence. For example:

Wrong: [Acetyl]-[Phospho]^2?EM[Oxidation]EVTSESPEK

Right: [Phospho]^2?[Acetyl]-EM[Oxidation]EVTSESPEK

### **Indicating a possible set of modification positions**

The position of a modification may be unknown but belong to a known set of possible sites. In this case, the possible positions for the modifications may be indicated. The rules that MUST be followed are:

(i) Groups of possible sites for a modification are represented immediately following the modification notation using the symbol #, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Note that the label prefix #XL is a special case that MUST be reserved for crosslinkers only.

(ii) A single preferred location for the modification must be specified, so that the sequence can be easily rendered in visualization tools. The preferred location for the modification is indicated by the position of the modification notation in the amino acid sequence.

In this example, ‘#g1’ is used as the arbitrary label:

EM[Oxidation]EVT[#g1]S[#g1]ES[Phospho#g1]PEK

This is read as a named group 'g1' indicates that a phosphorylation exists on either T5, S6 or S8, and S8 is the preferred location because the notation ‘Phospho’ is placed at this position.

The following example is not valid because a single preferred location must be chosen for a modification:

EM[Oxidation]EVT[#g1]S[Phospho#g1]ES[Phospho#g1]PEK

### **Representing ranges of positions for the modifications**

Ranges of amino acids as possible locations for the modifications may be represented using parentheses within the amino acid sequence. Some examples:

PROT(EOSFORMS)[+19.0523]ISK

PROT(EOC[Carbamidomethyl]FORMS)[+19.0523]ISK

Overlapping ranges represent a more complex case and are not yet supported, and so, the following example would NOT be valid:

P(ROT(EOSFORMS)[+19.0523]IS)[+19.0523]K

### **Indicating modification position preference and localisation scores**

There are two options to represent this type of information. The values of the modification localisation scores can be indicated in parentheses within the same group and brackets.

Example of proper localisation score usage:

EM[Oxidation]EVT[#g1(0.01)]S[#g1(0.09)]ES[Phospho#g1(0.90)]PEK

Scores for the modification position can be expressed as probabilities and/or FLR (False Localisation Rate), but the actual meaning of the scores is not reported. The preferred location of the modification notation reflects the value of the scores. If there is a tie in the value of the localisation scores, one preferred position needs to be chosen by the writer.

An additional option to represent localisation scores is to leave the position of the modification as unknown using the ‘?’ notation but report the localisation modification scores at specific sites.

Example of proper usage of localisation scores with unknown modification site notation:

[Phospho#s1]?EM[Oxidation]EVT[#s1(0.01)]S[#s1(0.09)]ES[#s1(0.90)]PEK

### **Representing scoring for ranges of positions for a modification**

Ranges of amino acids as possible locations for the modifications may also be accompanied by scoring using the same notation. Some examples:

PROT(EOSFORMS)[+19.0523#g1(0.01)]ISK[#g1(0.99)]

PR[#g1(0.91)]OT(EOC[Carbamidomethyl]FORMS)[+19.05233#g1(0.09)]ISK

## **Representation of multiple modifications in the same amino acid residue**

Currently, there is no need to chain two mods together on the same residue, since complex glycans are not explicitly supported (see Section 3.4). The solution in those rare cases not involving glycans is to have a single PSI-MOD/Unimod entry for the combination of mods.

## **Representation of global modifications**

This mechanism MAY be used for modifications that apply to all relevant residues in the peptide/protein amino acid sequence. These modifications MAY be represented by the use of the characters “<” and “>” on the left side of the sequences. A couple of use cases are envisioned:

### **Use Case 1: Representation of isotopes**

This might be used in the case of synthetic peptides with 100% incorporation.

Example: Consider extension for 13C on all residues:

Carbon 13: <13C>ATPEILTVNSIGQLK

Nitrogen 15: <15N>ATPEILTVNSIGQLK

Deuterium: <D>ATPEILTVNSIGQLK

The representation of multiple isotopes is also possible. They can be located in any order.

Both Carbon 13 and Nitrogen 15: <13C><15N>ATPEILTVNSIGQLK

Distributions of isotope masses could be supported in future work.

### **Use Case 2: Fixed protein modifications**

This mechanism can be useful especially in the case of full proteoforms. The affected amino acid MUST be indicated using @. If more than one residue were affected, they MUST be comma separated. Examples:

<[S-carboxamidomethyl-L-cysteine]@C>ATPEILTCNSIGCLK

<[MOD:01090]@C>ATPEILTCNSIGCLK

<[Oxidation]@C,M>MTPEILTCNSIGCLK

Fixed modifications MUST be written prior to ambiguous modifications, and similar to ambiguity notation, N-terminal modifications MUST be the last ones written, just next to the sequence.

The following examples would be valid:

<[MOD:01090]@C>[Phospho]?EM[Oxidation]EVTSECSPEK

<[MOD:01090]@C>[Acetyl]-EM[Oxidation]EVTSECSPEK

## **The information tag**

General information or comments can be encoded using the ‘info’ tag like:

ELV[INFO:AnyString]IS

ELV[info:AnyString]IS

The information represented in an ‘info’ tag is considered non-standard (e.g. any text besides unpaired brackets) and does not need to be parsed.

Example of proper ‘info’ tag usage:

ELVIS[Phospho|INFO:newly discovered]K

ELVIS[Phospho|INFO:newly discovered|INFO:really awesome]K

The following comment would be invalid because of an unpaired bracket:

ELVIS[Phospho|INFO:newly]discovered]K

## **Support for the joint representation of experimental data and its interpretation**

The pipe character “|” is used to represent protein modifications simultaneously with CV/ontology names and/or accession numbers, and delta masses. As explained in Section 4.2.5, Delta mass notation, it is possible to represent both canonical delta masses and experimental observations, allowing the representation of both interpretation (using CV/ontology names/accession numbers) and experimental observations (delta masses).

Examples:

ELVIS[U:Phospho|+79.966331]K

Showing both the interpretation and measured mass:

ELVIS[U:Phospho|Obs:+79.978]K

Other combinations between CV/ontology names, accession numbers, and delta masses using synonyms are allowed, though they MUST be synonymous terms. Some examples:

ELVIS[Phospho|O-phospho-L-serine]K

ELVIS[UNIMOD:21|MOD:00046]K

ELVIS[UNIMOD:21|Phospho]K

ELVIS[Phospho|O-phospho-L-serine|Obs:+79.966]K

Ambiguous cases are also allowed because they can be used to represent “comparable” information.

ELVIS[Obs:+79.966|Phospho|Sulfo]K

Highly different modifications SHOULD NOT be joined as it would be difficult for readers to correctly interpret. It is however acknowledged that readers can choose to implement the parsing in different ways. Some tools may always take CV terms, others could take delta masses, and so on.

# Pending Issues - Future developments

Additionally, there are several use cases that are NOT currently supported in the current version of the specification. These complications are left open in version 2.0 of the specification and will ideally be addressed in future versions, after the community has gained more experience with the common cases. The objective here is to document those cases appropriately and propose some possible solutions for representing the information in future versions of ProForma.

## **Representation of cyclic peptides**

Cyclic peptides are only currently supported if they can be represented using the supported CVs/ontologies for protein modifications. The following examples represent possible ways to represent cyclic peptides, but these solutions need to be formalised and PSI-MOD modifications created.

1) Cyclic peptide with C- and N-termini bound together at the peptide backbone level

Kalata B1 (PubChemID: 46231131, UniProtKB: P56254)

[*MOD:nnnnnn#*XL1]-RNGLPVCGETCVGGTCNTPGCTCSEPVCT-[#XL1]

where *MOD:nnnnnn* would be a new PSI-MOD term to represent backbone cyclisation involving the amidation between a C-terminal carboxylate and a N-terminal amine, with mass difference of O-1H-2 (-18 Da).

2) Cyclic peptide with C- and N-termini bound together at the peptide backbone level with 3 disulfide bonds

Retrocyclin 1 (PubChem ID 16130540). The exact structure is the following:

<https://pubchem.ncbi.nlm.nih.gov/compound/Retrocyclin-1#section=Biologic-Description&fullscreen=true>

[*MOD:nnnnnn*#XL1]-RC[MOD:00798.DS1]IC[MOD:00798.DS2]GRGIC[MOD:00798.DS2]RC[MOD:00798.DS1]IC[MOD:00798.DS3]GRGIC[MOD:00798.DS3]-[*#*XL1]

where *MOD:nnnnnn* would be a new PSI-MOD term to represent backbone cyclisation involving the amidation between a C-terminal carboxylate and a N-terminal amine, with a mass difference of O-1H-2 (-18 Da).

3) Cyclic peptide with C-terminal COOH condensed to a sidechain NH2

3a) peptide with no other PTM

LEIK[N6-(L-asparagyl)-L-lysine#XL1]KIPHDN[#XL1]

3b) A real case scenario: Topitracin (PubChem ID:6474109)

[[N-[2-[1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-Leucine]-LE[D-Glutamic acid]IK[M:N6-(L-asparagyl)-L-lysine#XL1]K[M:D-Ornithine]I[M:D-alloisoleucine]P[D-Phenylalanine]HD[M:D-Aspartic acid]N[#XL1]

## **Representation of ambiguity when different glycans are attached to the same amino acid sequence**

Multiply glycosylated peptides, especially under vibrational/collisional dissociation, may fragment in ways that allow sequencing the peptide backbone without completely characterizing the glycan sites. Instead, only the aggregate composition can be determined based on the precursor peptide mass. In such cases, only the glycosylation may be known, by motif for N-glycan or there may be several possible sites. Alternatively, the total number of glycosylation sites may be unknown (O-glycans), with the aggregate glycan composition may be spread across positions in unknown proportions.

There is a need to express that a site is a possible glycosylation site as well as a mechanism to express the total amount of glycan composition shared across these sites. The latter is achieved by using a labile modification to prefix the total composition. There are multiple proposals for expressing putative site assignment:

Proposal 1. Use PSI-MOD glycosylated residue modifications.

{Glycan:Hex 10 HexNAc 4}YPVLN[MOD:00006]VTMPN[MOD:00006]NSNGKFDK

This peptide hosts two N-glycans, where the glycan class is known from the required motifs on the sequence, and that it is multiply glycosylated because no single N-glycan with the aggregate composition is biosynthetically feasible. This proposal denotes the inferred glycosylation sites using the PSI-MOD “N-glycosylated residue” term. This forces the reader to treat this group differently, where the modification is inferred to be the labile glycan modification and that the modification may be split amongst each site, assigning zero or more monosaccharides to each group position.

Pros:

* Conveys extra metadata about the glycan type
* Uses an existing term

Cons:

* Introduces new semantics for a modification that is not explicitly conveyed notationally, namely that this modification is not observable, but just encodes positional information.
* For complex and ambiguous O-glycopeptides, this method would pull double-duty with ambiguity notation.

Proposal 2. Use ambiguity groups.

{Glycan:Hex 10 HexNAc 4}YPVLN[#g1]VTMPN[Glycan#g1]NSNGKFDK

The same case with Proposal 1, but instead of adding extra baggage to an existing term, this proposal uses ambiguity groups to denote possible positions, and mark one group with a new “Glycan” key, which adds the same labile modification inference step.

Pros:

* Uses an ambiguity-specific mechanism to signal ambiguity.

Cons:

* Adds a new component to ambiguity group interpretation that parsers must now be prepared to handle.
* No ability to communicate glycan type at the site level.

A complex O-glycopeptide example

{Glycan:Hex 5 HexNAc 5}PEPSTAT[Glycan#g1]IS[#g1]T[#g1]ICS[#g1]S[#g1]T[#g1]RIKES[#g1]IT[#g1]ES[#g1]

Fragmentation may demonstrate that some S/T residues are not putative sites, while the distribution of glycan composition is still not known amongst the remaining sites. The true solution might be:

PEPSTATISTICS[Glycan:HexNAc Hex]S[Glycan:HexNAc Hex]TRIKES[Glycan:HexNAc Hex]IT[Glycan:HexNAc Hex]ES[Glycan:HexNAc Hex]

Or PEPSTATISTICSS[Glycan:HexNAc 2 Hex 2]TRIKES[Glycan:HexNAc Hex]IT[Glycan:HexNAc Hex]ES[Glycan:HexNAc Hex], or any permutation thereof.

Proposal 3. Use cross-linking-like notation

{Glycan:Hex 10 HexNAc 4.G1}YPVLN[Glycan:#G1]VTMPN[Glycan:#G1]NSNGKFDK

The only differentiating feature of this proposal from Proposal 2 is that it isolates the notational change solely within the Glycan tag handling, which reduces the burden on implementers who do not want to support glycosylation.

## **Representation of rare amino acids not supported by the one letter code**

This use case is currently not supported. These SHOULD be handled through their representations in one of the supported ontologies/CVs.

## **Representation of average masses**

During the development of the format, it was acknowledged that, in the case of top-down proteomics approaches, there could be cases where monoisotopic masses are unknown, and then average masses need to be used. At the moment, monoisotopic masses are the only ones formally allowed, but this MAY have to change in future changes.

## **Representation of lipids**

These SHOULD be handled through their representations in one of the supported ontologies/CVs. However, a similar mechanism to the one described in Section 4.2.8, Representation of glycan composition, could be implemented for lipid molecules.

Examples:

SEQUEN[Lipid:OleicAcid]CE

SEQUEN[Lipid:PalmiticAcid]CE

It is envisioned that when this use case becomes a clear requirement in the future, a dedicated working group can extend these specific guidelines.

## **Distribution of isotopes in the sequence**

The representation of the distributions of isotopes for global modifications (Section 4.6) is not supported in the current version of the specification. A mechanism will need to be envisioned to support this use case in future versions.

## **Representation of molecular formula**

Elemental formulas are supported by the current version of ProForma (Section 4.2.7), and molecular formulas may be supported in the future if it would prove helpful. For example, specifying branching in a PTM structure. A molecular formula may include repeated (condensed) sections using parentheses and an extra cardinality.

Examples:

CH3(CH2)4CH3

SEQUEN[Formula:CH3(CH2)4CH3]CE

## **Representation of overlapping range of possible modification localizations**

Notation of ambiguous localization currently supports non-overlapping ranges. A possible representation of overlapping ranges, that may be considered in the future, uses a grouping tag for both parentheses.

Examples:

PROT([#g1]EOC[Carbamidomethyl]FORMS)[+19.0523#g1]ISK

PR([#g1]OT([#g2]EOC[Carbamidomethyl]FOR)[+19.0523#g1]MS)[+19.0523#g2]ISK

PROT([#g1]([#g2]EOC[Carbamidomethyl]FORMS)[+19.0523#g2]IS)[+19.0523#g1]K

## **Representation of ambiguous crosslinker modification** positions

Notation for ambiguous crosslinker modification positions is not supported in this version of ProForma but may be supported in the future.

# Appendix I. Levels of Compliance

Due to the multiple use cases supported in this specification, it is not expected that all implementers can provide support to all the supported features from ProForma version 2. To facilitate adoption and separate some of the use cases, there are multiple “levels of compliance” and extensions for ProForma.

1) Base Level Support

Represents the lowest level of compliance, this level involves providing support for:

- Amino acid sequences

- Protein modifications using two of the supported CVs/ontologies: Unimod and PSI-MOD.

- Protein modifications using delta masses (without prefixes)

- N-terminal, C-terminal and labile modifications.

- Ambiguity in the modification position, including support for localisation scores.

- INFO tag.

2) Additional Separate Support

These features are independent from each other:

- Unusual amino acids (O and U).

- Ambiguous amino acids (e.g. X, B, Z). This would include support for sequence tags of known mass (using the character X).

- Protein modifications using delta masses (using prefixes for the different CVs/ontologies).

- Use of prefixes for Unimod (U:) and PSI-MOD (M:) names.

- Support for the joint representation of experimental data and its interpretation.

3) Top Down Extensions

- Additional CV/ontologies for protein modifications: RESID (the prefix R MUST be used for RESID CV/ontology term names)

- Chemical formulas (this feature occurs in two places in this list).

4) Cross-Linking Extensions

- Cross-linked peptides (using the XL-MOD CV/ontology, the prefix X MUST be used for XL-MOD CV/ontology term names).

5) Glycan Extensions

- Additional CV/ontologies for protein modifications: GNO (the prefix G MUST be used for GNO CV/ontology term names)

- Glycan composition.

- Chemical formulas (this feature occurs in two places in this list).

6) Spectral Support

- Charge and chimeric spectra are special cases (see Appendix I).

- Global modifications (e.g., every C is C13).

Additionally, see Section 5 “Pending Issues - Future developments” for features not yet formally supported in this version of the specification. In the future, there could be additional extensions, e.g., for lipid molecules.

# Appendix II: Extensions to improve the representation of PSMs in mass spectra

This appendix is not relevant for the representation of peptidoforms and proteoforms, but rather presents techniques for representing PSMs (that is, peptidoforms and proteoforms together with mass spectra).

## **Representation of the ion charges**

The charge value MAY be optionally indicated in the C-terminal end of the amino acid sequence, by using the forward slash (/) character. Examples:

EMEVEESPEK/2

EM[U:Oxidation]EVEES[U:Phospho]PEK/3

[U:iTRAQ4plex]EM[U:Oxidation]EVNES[U:Phospho]PEK[U:iTRAQ4plex]-[U:Methyl]/3

By default, a positive number n will imply a molecular ion that is n-times protonated

SEQUENCE/2 Means [SEQUENCE(neutral) + 2 protons ] and is doubly charged: [M+2H+]2+

By default, a negative number n will imply a molecular ion that is n-times deprotonated

SEQUENCE/-2 Means [SEQUENCE(neutral) - 2 protons ] and is doubly charged: [M-2H+]2-

When the charge derives from the addition or the removal of another ion, this ionic species SHOULD be provided after the charge state number. Examples include a Na+ adduct, the addition of one electron, the removal of a OH-, the addition of an iodine ion, and a radicalisation.

EMEVEESPEK/2[+2Na+,+H+]

EMEVEESPEK/1[+2Na+,-H+]

EMEVEESPEK/-2[2I-]

EMEVEESPEK/-1[+e-]

## **Representation of multiple peptidoform assignments in chimeric spectra**

In bottom-up approaches, in the case of chimeric spectra, more than one peptidoform sequence MAY be potentially assigned to a single mass spectrum. In this case, multiple peptidoform sequences MUST be separated by the plus sign (+). Example:

EMEVEESPEK/2+ELVISLIVER/3

# Appendix III. Glossary of terms used in the specification

The objective here is to provide a list of the keys used in the document, so that a summary view is available for implementers.

1- Protein modifications

1.1- (Non-labile) protein modifications are represented by using brackets [] + CV/ontology parameter names (for PSI-MOD/ Unimod).

For RESID (R:), XL-MOD (X:) and GNO (G:), extra prefixes MUST be used before the CV parameter names. For PSI-MOD (M:) and Unimod (U:), they are optional.

EM[Oxidation]EVEES[Phospho]PEK

EM[R: Methionine sulfone]EVEES[O-phospho-L-serine]PEK

EMEVTK[X:DSS#XL1]SESPEK (see Section 4.2.3)

EM[U:Oxidation]EVEES[U:Phospho]PEK

1.2- Non-labile protein modifications can also be reported using brackets [] including +/- Delta mass values.

EM[+15.9949]EVEES[+79.9663]PEK

The use of prefixes for reporting delta masses coming from ontologies/CVs MAY be supported (only in Advanced mode).

EM[U:+15.995]EVEES[U:+79.966]PEK

Experimentally observed delta masses are reported using the prefix [Obs:].

EM[U:+15.995]EVEES[Obs:+79.978]PEK

1.3- Sequence gaps of known mass MAY also be indicated using the amino acid X + brackets [] including the delta mass value of the tag.

RTAAX[+367.0537]WT

1.4- (Labile) protein modifications are indicated at the left side of the sequence using curly brackets {}.

{Glycan:Hex}EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

1.5- N-terminal and C-terminal modifications are indicated using a dash (-) on the left/right part of the sequence, respectively.

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

1.6- Representation of global fixed modifications uses the “at” (@) character.

<[S-carboxamidomethyl-L-cysteine]@C>ATPEILTCNSIGCLK

<[MOD:01090]@C>ATPEILTCNSIGCLK

2- Ambiguity in the modification position:

2.1- Unknown modification positions can be indicated with the sign ‘?’.

[Phospho]?EM[Oxidation]EVTSESPEK

[Phospho][Phospho]?[Acetyl]-EM[Oxidation]EVTSESPEK

2.2- Groups of modifications can be linked using arbitrary labels. The preferred location for the modification is indicated by the actual position of the modification tag or name in the amino acid sequence. Scores on the modification position can be indicated using parentheses.

EM[Oxidation]EVT[#g1]S[#g1]ES[Phospho|#g1]PEK

EM[Oxidation]EVT[#g1(0.01)]S[#g1(0.09)]ES[Phospho|#g1(0.90)]PEK

2.3- The cases reported in 6.1 and 6.2 can be combined to represent scores of the modification position.

[Phospho|#s1]?EM[Oxidation]EVT[#s1(0.01)]S[#s1(0.90)]ES[#s1(0.90)]PEK

2.4- A range of positions for a modification can be indicated in the amino acid sequence using a parenthesis for those amino acids involved.

PROT(EOSFORMS)[+19.0523]ISK

PROT(EOC[Carbamidomethyl]FORMS)[+19.0523]ISK

3- Chemical formulas of small molecules may be specified using the descriptor [Formula:].

3.1- A formula will be composed of pairs of atoms and their corresponding cardinality. Pairs MAY be separated by spaces.

SEQUEN[Formula:C12H20O2]CE

3.2- Cardinalities must be a positive or negative integer values. Zero is not supported. If a cardinality is not included with an atom, it is assumed to be +1.

SEQUEN[Formula:HN-1O2]CE

3.3- Isotopes will be handled by prefixing the atom with its isotopic number in square brackets.

Here, 2 12C atoms are replaced by 2 13C atoms:

SEQUEN[Formula:[13C2][12C-2]H2N]CE (here 2 12C atoms are replaced by 2 13C atoms)

4- Glycan residues (generic monosaccharides) can be represented using the descriptor

“Glycan”[Glycan:].

SEQUEN[Glycan:HexNAc]CE

5- Cross-Linked Peptides

Using the XL-MOD CV, crosslinked sites MUST be represented immediately after the modification notation using the prefix #xl, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Cross-linker modification notations MUST be mentioned once only.

EMEVTK[XLMOD:02001#XL1]SESPEK[#XL1]

“Dead end” crosslink: EMEVTK[XLMOD:02001#XL1]SESPEK

Inter-protein or inter-chain connections are supported using \\ to separate the crosslinked peptides.

SEK[XLMOD:02001#XL1]UENCE\\EMEVTK[XLMOD:02001#XL1]SESPEK

6- Joint representation of experimental data and its interpretation uses the pipe “|” character.

ELVIS[Phospho|+79.966331]K

ELVIS[Phospho|Obs:+79.978]K

7- INFO Tag. The information represented in between an INFO tag is considered non-standard (e.g. any text except a close bracket character) and does not need to be parsed. It is equivalent to a #comment in source code.

ELV[INFO:xxxxx]IS

8- Representation of isotopes: They can be represented using <> including the concrete isotope in between.

<13C>ATPEILTVNSIGQLK

9- Representation of mass spectra features:

9.1- Charges for spectra are indicated at the end of the sequence using /.

EMEVEESPEK/2

9.2 Chimeric spectra are indicated using the plus “+” character.

EMEVEESPEK+ELVISLIVER

EMEVEESPEK/2+ELVISLIVER/3

## 

# Authors Information

Juan Antonio Vizcaíno

European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, United Kingdom

[juan@ebi.ac.uk](mailto:juan@ebi.ac.uk)

Eric W. Deutsch

Institute for Systems Biology, Seattle WA, USA

[edeutsch@systemsbiology.org](mailto:edeutsch@systemsbiology.org)

Ryan Fellers

Northwestern University, Evanston IL, USA

[ryan.fellers@northwestern.edu](mailto:ryan.fellers@northwestern.edu)

Anthony J. Cesnik

Stanford University, Stanford CA, USA

[cesnik@stanford.edu](mailto:cesnik@stanford.edu)

Joshua A. Klein

Boston University, Boston MA, USA

[joshua.adam.klein@gmail.com](mailto:joshua.adam.klein@gmail.com)

Tim Van Den Bossche

Ghent University, Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium

[Tim.VanDenBossche@ugent.be](mailto:Tim.VanDenBossche@ugent.be)

Ralf Gabriels

Ghent University, Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium

[ralf.gabriels@ugent.be](mailto:ralf.gabriels@ugent.be)

Pierre-Alain Binz

CHUV Lausanne University Hospital, Lausanne, Switzerland

[Pierre-Alain.Binz@chuv.ch](mailto:Pierre-Alain.Binz@chuv.ch)

Yasset Perez-Riverol

European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, United Kingdom

[yperez@ebi.ac.uk](mailto:yperez@ebi.ac.uk)

Jeremy Carver

University of California San Diego, San Diego CA, USA

[jcarver@ucsd.edu](mailto:jcarver@ucsd.edu)

Shin Kawano

Toyama University of International Studies, Toyama, Japan

[kawano@tuins.ac.jp](mailto:kawano@tuins.ac.jp)

Benjamin Pullman

University of California San Diego, San Diego CA, USA

[bpullman@eng.ucsd.edu](mailto:bpullman@eng.ucsd.edu)

Nuno Bandeira

University of California San Diego, San Diego CA, USA

[bandeira@ucsd.edu](mailto:bandeira@ucsd.edu)

Paul M. Thomas

Northwestern University, Evanston IL, USA

[paul-thomas@northwestern.edu](mailto:paul-thomas@northwestern.edu)

Richard Leduc

Northwestern University, Evanston IL, USA

[richard.leduc@northwestern.edu](mailto:richard.leduc@northwestern.edu)

# Contributors

In addition to the authors, a number of additional contributions have been made during the preparation process. The contributors who actively participated to the recommendation documentation are:

- Luis Mendoza, Institute for Systems Biology, Seattle, WA, USA

- Gerben Menschaert, Ghent University, Ghent, Belgium

- Jim Shofstahl, Thermo Fisher Scientific, San Jose, CA, USA

- Zhi Sun, Institute for Systems Biology, Seattle, WA, USA

- Leah V. Schaffer, University of Wisconsin-Madison, Madison, WI, USA

- Michael R. Shortreed, University of Wisconsin-Madison, Madison, WI, USA

- Brian L. Frey, University of Wisconsin-Madison, Madison, WI, USA

- Veit Schwämmle, University of Southern Denmark, Odense, Denmark

# Intellectual Property Statement

The PSI takes no position regarding the validity or scope of any intellectual property or other rights that might be claimed to pertain to the implementation or use of the technology described in this document or the extent to which any license under such rights might or might not be available; neither does it represent that it has made any effort to identify any such rights. Copies of claims of rights made available for publication and any assurances of licenses to be made available, or the result of an attempt made to obtain a general license or permission for the use of such proprietary rights by implementers or users of this specification can be obtained from the PSI Chair.

The PSI invites any interested party to bring to its attention any copyrights, patents or patent applications, or other proprietary rights which may cover technology that may be required to practice this recommendation. Please address the information to the PSI Chair (see contacts information at PSI website).

# Copyright Notice

Copyright (C) Proteomics Standards Initiative (2020). All Rights Reserved.

This document and translations of it may be copied and furnished to others, and derivative works that comment on or otherwise explain it or assist in its implementation may be prepared, copied, published and distributed, in whole or in part, without restriction of any kind, provided that the above copyright notice and this paragraph are included on all such copies and derivative works. However, this document itself may not be modified in any way, such as by removing the copyright notice or references to the PSI or other organizations, except as needed for the purpose of developing Proteomics Recommendations in which case the procedures for copyrights defined in the PSI Document process must be followed, or as required to translate it into languages other than English.

The limited permissions granted above are perpetual and will not be revoked by the PSI or its successors or assigns.

This document and the information contained herein is provided on an "AS IS" basis and THE PROTEOMICS STANDARDS INITIATIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY THAT THE USE OF THE INFORMATION HEREIN WILL NOT INFRINGE ANY RIGHTS OR ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE."

# Glossary

All non-standard terms are already defined in detail in section 3.

# References

1. Binz, P.A., Shofstahl, J., Vizcaino, J.A., Barsnes, H., Chalkley, R.J., Menschaert, G., Alpi, E., Clauser, K., Eng, J.K., Lane, L. *et al.* (2019) Proteomics Standards Initiative Extended FASTA Format. *Journal of proteome research*, 18, 2686-2692.

2. LeDuc, R.D., Schwammle, V., Shortreed, M.R., Cesnik, A.J., Solntsev, S.K., Shaw, J.B., Martin, M.J., Vizcaino, J.A., Alpi, E., Danis, P. *et al.* (2018) ProForma: A Standard Proteoform Notation. *Journal of proteome research*, 17, 1321-1325.